Latest news with #PYCTherapeutics
News.com.au
5 days ago
- Business
- News.com.au
Closing Bell: ASX holds ground near all-time high as defence stocks soar
ASX slips just 12.3 points, remaining near all-time high Healthcare leads losses as Trump raises tariff spectre Gains in gold and consumer discretionary soften losses Profit takers stay their hands When markets hit new closing highs, it's common for traders to see it as an opportunity to capitalise on gains. Stocks are – theoretically – at their highest. What better time to cash in? While the ASX 200 fell 0.14% today, the bulls are looking very much in control. Losses were limited to a small 12.3-point loss, a sniff in the wind compared to the almost 200 points the market has gained in just three days. That's not to say we won't see a bigger dip tomorrow – volatility is the name of the game these days, and Trump is continuing to fan the flames with another tariff hit on India just yesterday. As for today, six of 11 sectors were down with particular weakness in healthcare stocks. Materials slid marginally lower but gains in gold stocks and the consumer discretionary sector stemmed the bleeding. Healthcare and defence stocks move in opposite directions Trump's recent comments that big tariffs are on the horizon for the industry are likely playing a part in healthcare's woes today. "In one year, one and a half years maximum, it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country," the US President told CNBC in an interview. Clarity Pharmaceuticals (ASX:CU6) fell 5.8%, Tetratherix (ASX:TTX) 6.2% and PYC Therapeutics (ASX:PYC) 4.6%. Health small cap IDT Australia (ASX:IDT) plunged 17.8% after the abrupt resignation of its CEO with immediate effect. The company's net losses are also increasing, up 38% to $7.5m year-on-year. Management says the losses are due to one-off bad debts and expenses related to new contracts. Moving against the tide, Imricor Medical Systems (ASX:IMR) added 8.7%. Perhaps a little ironically considering healthcare's losses, two defence industry stocks were among the biggest upward movers today. Unmanned drone (UAV) firm Elsight (ASX:ELS) added 10.9% alongside remote weapon system specialist Electro Optic Systems (ASX:EOS), which climbed 9.3%. Outside of the weapons and armament subsector, SKS Technologies (ASX:SKS) lifted 8.1% after exceeding profit guidance by more than 15% for FY25 last week. Tolling and service provider EROAD (ASX:ERD) also continued its hike, soaring 31.6% and up a whopping 99% for the year to date. All in all, it's been a solid week for the ASX so far, up more than 1% over the past five trading days. ASX rival Cboe muscles in on Aussie share market The Australian Securities Exchange itself finished out the day a full 8.6% lower. A one-two punch of self-inflicted blunders and rising competition set the bourse operator reeling. Yesterday's mix-up with TPG Telecom and TPG Capital was bad enough, but today ASIC flagged it was in the final stages of consideration for a listing market application for Cboe Australia. The subsidiary of Cboe Global Markets is looking to end the ASX's monopoly on Aussie stock listings, and ASIC seems to be in full support. The company already accounts for about 20% or $1.5 billion of our total equity trading volume as a trading market operator. ASIC chair Joe Longo said that Australian capital markets are facing intensifying global competition for capital and listings but remain healthy and hale. 'As superannuation funds grow and investors seek opportunities, our actions will help keep our markets efficient, innovative and attractive, supporting economic growth for all Australians,' he said. Perhaps it won't be too much longer until we're tracking multiple share markets here on the daily wrap. Yay? ASX Leaders Today's best performing stocks (including small caps): Code Name Last % Change Volume Market Cap RLG Roolife Group Ltd 0.007 75% 1.54E+08 $6,371,125 MTL Mantle Minerals Ltd 0.0015 50% 1000000 $6,447,446 BMG BMG Resources Ltd 0.011 38% 24298471 $6,755,177 RHY Rhythm Biosciences 0.13 37% 9529722 $26,987,659 ROG Red Sky Energy. 0.004 33% 205896 $16,266,682 LIN Lindian Resources 0.125 33% 30664878 $111,241,690 KM1 Kalimetalslimited 0.15 30% 202308 $9,527,457 SHO Sportshero Ltd 0.035 30% 5311325 $21,686,238 IFM Infomedia Ltd 1.675 27% 34845066 $499,513,991 ALV Alvomin 0.029 26% 457314 $4,491,091 ERA Energy Resources 0.0025 25% 703738 $810,792,482 H2G Greenhy2 Limited 0.02 25% 1107248 $11,006,589 TMX Terrain Minerals 0.0025 25% 500000 $5,063,629 WBE Whitebark Energy 0.005 25% 100200 $2,802,231 BTM Breakthrough Minsltd 0.13 24% 505828 $7,220,923 TOU Tlou Energy Ltd 0.026 24% 3465 $27,270,271 WTM Waratah Minerals Ltd 0.56 22% 7708511 $107,415,642 LMS Litchfield Minerals 0.12 20% 15390 $2,904,606 AJX Alexium Int Group 0.006 20% 408907 $7,932,143 ALM Alma Metals Ltd 0.006 20% 581771 $9,253,686 AN1 Anagenics Limited 0.006 20% 209032 $2,481,602 CZN Corazon Ltd 0.003 20% 74871454 $2,961,431 TEG Triangle Energy Ltd 0.003 20% 7123662 $5,223,085 JAN Janison Edu Group 0.2025 19% 287252 $44,181,003 AZ9 Asianbatterymet PLC 0.038 19% 2732082 $13,814,328 In the news… Building efficiency provider EPX (ASX:EPX) has lifted its annual recurring revenue by 14% in the 2025 financial year, now $15.5m. The company also expanded its annual contract value (an indication of potential future revenue) by 10% to $17.6m. The growth was based on a 35% expansion in site numbers, lifting from 547 in June 2024 to 740 sites this year following a strategic restructure of EPX's sales sector. Augmented reality training provider XReality Group (ASX:XRG) has locked in two new contracts for its Operator XR AI training solution. The first contract comes in the form of a merit-based grant with the Australian government's Industry Growth Program. The government is offering $2.1m over 24 months, with the goal of accelerating XRG's virtual reality training offering. The second is the largest order for Operator XR's OP-2 systems to date. XRG inked the deal with the Texas Department of Public Safety for a five-year period. The initial order is valued at $4.3m, with a $1.4m option for additional support services down the track. Sustainable packaging specialist Papyrus Australia (ASX:PPY) is moving into the next stage of commercialisation and product development, appointing Daniel Schmidt as its new CEO. The company recently completed a successful trial of new banana fibre-based boards and flat paper products in response to commercial interest, and fired up its Rapid Prototyping & R&D Facility in partnership with the University of South Australia. ASX Laggards Today's worst performing stocks (including small caps): Code Name Last % Change Volume Market Cap ATX Amplia Therapeutics 0.175 -27% 30921029 $116,754,486 ACS Accent Resources NL 0.006 -25% 110800 $3,916,298 AUK Aumake Limited 0.003 -25% 10170000 $12,093,435 CR9 Corellares 0.003 -25% 61335 $4,029,079 CT1 Constellation Tech 0.0015 -25% 33229 $2,949,467 JAY Jayride Group 0.003 -25% 495111 $5,711,556 PAB Patrys Limited 0.0015 -25% 1000000 $4,731,620 ASE Astute Metals NL 0.017 -23% 11957646 $13,599,294 BYH Bryah Resources Ltd 0.004 -20% 1122958 $5,142,663 DDT DataDot Technology 0.004 -20% 1 $6,054,764 PIL Peppermint Inv Ltd 0.002 -20% 305 $5,752,724 ZEU Zeus Resources Ltd 0.013 -19% 7817111 $11,478,986 EVR Ev Resources Ltd 0.009 -18% 349525 $24,502,537 HMI Hiremii 0.043 -17% 49090 $7,855,766 IND Industrialminerals 0.125 -17% 40006 $12,048,375 NOX Noxopharm Limited 0.1 -17% 242338 $35,068,554 AAU Antilles Gold Ltd 0.005 -17% 19242149 $14,274,408 FAU First Au Ltd 0.005 -17% 2235248 $12,457,748 JAV Javelin Minerals Ltd 0.0025 -17% 1561666 $18,756,675 MEL Metgasco Ltd 0.0025 -17% 46339 $5,511,260 EDEDA Eden Inv Ltd 0.033 -15% 748473 $8,014,268 CMG Criticalmineralgrp 0.14 -15% 7757 $14,939,820 PL3 Patagonia Lithium 0.034 -15% 515 $4,776,414 LCL LCL Resources Ltd 0.006 -14% 1000000 $8,394,800 PLC Premier1 Lithium Ltd 0.006 -14% 6853560 $2,576,424 In Case You Missed It Energy Transition Minerals (ASX:ETM) is moving to acquire the Penouta tin-tantalum-niobium mine in Galicia, Spain, which presents the opportunity to deliver early production and cashflow. Trigg Minerals (ASX:TMG) is expanding into tungsten, acquiring the Tennessee Mountain project in Nevada. Anson Resources (ASX:ASN) has produced strong flow results from testing at its Bosydaba#1 exploration well in Utah. TG Metals (ASX:TG6) has combined recent soil sampling results with historical drill results to generate compelling new drill targets at the Van Uden gold project in WA. Infinity Mining (ASX:IMI) is sketching out a kilometre-long corridor prospective for gold at the Cangai project's Sir Walter Scott prospect, with rock chip results up to 68.6g/t gold. Nine of 12 graded above 1 g/t gold, consistent with historical results. Nova Minerals' (ASX:NVA) ore sorting test work has put the Australian junior on track to potentially become the first fully integrated antimony producer in the US. Tryptamine Therapeutics (ASX:TYP) has secured a key regulatory approval to supply its IV-psilocin drug to Swinburne University for a world-first binge eating disorder trial. Xero's $3.9b Melio deal has eyes turning to the next potential B2B payments star. Trading Halts
Yahoo
01-05-2025
- Business
- Yahoo
High Growth Tech Stocks In Australia With Promising Potential
The Australian market has shown resilience with the ASX200 closing up 0.24% at 8,145 points, driven by a notable surge in the IT sector which rose by 4%, highlighting investor confidence in technology stocks amidst mixed performances across other sectors. In this dynamic environment, high growth tech stocks stand out for their potential to capitalize on technological advancements and market trends, making them attractive considerations for investors looking to navigate the evolving landscape. Name Revenue Growth Earnings Growth Growth Rating Gratifii 42.14% 113.99% ★★★★★★ Pro Medicus 22.19% 23.49% ★★★★★★ WiseTech Global 20.37% 25.23% ★★★★★★ BlinkLab 65.54% 64.35% ★★★★★★ Wrkr 57.01% 116.83% ★★★★★★ AVA Risk Group 29.15% 108.15% ★★★★★★ Pointerra 50.42% 159.12% ★★★★★☆ Echo IQ 84.54% 87.08% ★★★★★★ SiteMinder 21.09% 65.36% ★★★★★★ Advanced Health Intelligence 166.58% 178.92% ★★★★★☆ Click here to see the full list of 46 stocks from our ASX High Growth Tech and AI Stocks screener. Here we highlight a subset of our preferred stocks from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for genetic diseases, with a market cap of A$647.36 million. Operations: The company generates revenue primarily from the discovery and development of novel RNA therapeutics, amounting to A$24.99 million. PYC Therapeutics, navigating through the competitive landscape of biotech innovation in Australia, is steering towards profitability with an anticipated growth in annual earnings by 24.31% over the next three years. This growth trajectory is significantly above the average market forecast and underscores PYC's strategic focus on research and development, crucial for pioneering treatments like PYC-003. Recently, the company initiated a Phase 1a study for this drug candidate, marking a pivotal step in its clinical advancements. Despite current unprofitability and shareholder dilution reflected by a recent equity offering of AUD 145.82 million, PYC's revenue has surged to AUD 12.69 million from AUD 9.12 million year-over-year—an impressive leap that outpaces general market trends in Australia by more than double the rate (12.6% vs 5.6%). This suggests not only resilience but also an aggressive pursuit of breakthroughs that could potentially reshape therapeutic approaches within their sector. Navigate through the intricacies of PYC Therapeutics with our comprehensive health report here. Assess PYC Therapeutics' past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Qoria Limited is engaged in the marketing, distribution, and sale of cyber safety products and services across various regions including Australia, New Zealand, the United Kingdom, the United States, Europe, and other international markets with a market capitalization of A$510.11 million. Operations: Qoria Limited generates revenue primarily through the provision of cyber safety services, amounting to A$108.72 million. The company's operations span multiple regions including Australia, New Zealand, the UK, the US, and Europe. Qoria is navigating a transformative phase, with revenue growth projected at 16.1% annually, outpacing the Australian market average of 5.6%. Despite current unprofitability, this tech firm is on a trajectory to profitability within three years, supported by an impressive annual earnings growth forecast of 64.62%. Recent financials show a significant reduction in net loss to AUD 9.6 million from AUD 28.2 million year-over-year and a rise in sales to AUD 55.4 million from AUD 48.5 million, indicating robust operational improvements and market adaptation strategies that could reshape its industry standing in the near future. Unlock comprehensive insights into our analysis of Qoria stock in this health report. Understand Qoria's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★★★ Overview: WiseTech Global Limited develops software solutions for the logistics execution industry across various regions, with a market cap of A$29.37 billion. Operations: The company provides software solutions tailored to the logistics execution industry, generating revenue primarily from its Internet Software & Services segment, which amounts to $698.66 million. WiseTech Global's strategic bolstering of its leadership with the appointment of Zubin Appoo as Deputy Chief Innovation Officer underscores its commitment to innovation and operational efficiency in the tech sector. This move aligns with WiseTech's robust financial performance, evidenced by a 20.4% annual revenue growth and an impressive 25.2% rise in earnings, significantly outpacing the broader Australian market. Additionally, WiseTech's focus on R&D is evident from its spending, which has been pivotal in maintaining technological leadership and fostering product development that meets evolving global logistics demands. These concerted efforts not only enhance WiseTech's competitive edge but also signal strong future prospects amidst dynamic market challenges. Take a closer look at WiseTech Global's potential here in our health report. Review our historical performance report to gain insights into WiseTech Global's's past performance. Access the full spectrum of 46 ASX High Growth Tech and AI Stocks by clicking on this link. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:PYC ASX:QOR and ASX:WTC. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
04-03-2025
- Business
- Yahoo
Exploring High Growth Tech Stocks In Australia March 2025
Amidst a volatile Australian market, with key sectors like energy and utilities facing significant downturns and health care showing modest gains, investors are navigating a complex landscape influenced by global trade tensions and fluctuating commodity prices. In this environment, identifying high growth tech stocks requires careful consideration of factors such as innovation potential, adaptability to market changes, and resilience against broader economic uncertainties. Name Revenue Growth Earnings Growth Growth Rating Telix Pharmaceuticals 20.02% 33.35% ★★★★★★ Gratifii 42.14% 113.99% ★★★★★★ WiseTech Global 20.53% 25.64% ★★★★★★ Pro Medicus 22.56% 23.74% ★★★★★★ BlinkLab 65.54% 64.35% ★★★★★★ Wrkr 51.62% 116.83% ★★★★★★ AVA Risk Group 29.15% 108.15% ★★★★★★ Mesoblast 56.15% 62.13% ★★★★★★ SiteMinder 21.12% 65.36% ★★★★★★ Opthea 58.66% 66.98% ★★★★★★ Click here to see the full list of 54 stocks from our ASX High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★☆☆ Overview: PYC Therapeutics Limited is a drug-development company focused on discovering and developing novel RNA therapeutics to treat genetic diseases in Australia, with a market cap of A$559.93 million. Operations: The company generates revenue primarily through the discovery and development of novel RNA therapeutics, amounting to A$24.99 million. PYC Therapeutics, a contender in Australia's high-growth tech sector, is navigating through its early unprofitable phase with strategic moves aimed at future profitability. With an annual revenue growth forecast at 10.1%, PYC outpaces the broader Australian market's 5.4% growth rate, showcasing its potential amidst industry challenges. The company recently reported a half-year revenue jump to AUD 12.69 million from AUD 9.12 million year-over-year but also noted an increased net loss of AUD 25.57 million, reflecting significant reinvestment and R&D expenses crucial for long-term gains. Additionally, a recent follow-on equity offering of AUD 145.81 million underscores their aggressive capital raising efforts to fuel research and expansion strategies essential for transitioning into profitability projected within three years. Delve into the full analysis health report here for a deeper understanding of PYC Therapeutics. Explore historical data to track PYC Therapeutics' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Qoria Limited is engaged in the marketing, distribution, and sale of cyber safety products and services across Australia, New Zealand, the United Kingdom, the United States, Europe, and other international markets with a market cap of A$577.60 million. Operations: Qoria focuses on providing cyber safety solutions globally, with key markets in Australia, New Zealand, the UK, the US, and Europe. The company generates revenue through the sale and distribution of its products and services aimed at enhancing digital security for consumers. Qoria, amidst a challenging landscape for unprofitable tech firms in Australia, shows promising signs with its strategic focus on becoming profitable within three years. The company's revenue is expected to grow at 15.7% annually, outpacing the Australian market's average of 5.4%. This growth is underpinned by a significant reduction in net losses — down from AUD 28.2 million to AUD 9.6 million year-over-year — and an aggressive R&D investment strategy that aligns with industry shifts towards software innovation and service delivery models. These efforts are crucial as Qoria navigates its path toward profitability, leveraging both product development and market expansion to solidify its standing in the high-tech sector. Unlock comprehensive insights into our analysis of Qoria stock in this health report. Examine Qoria's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★★ Overview: WiseTech Global Limited develops and provides software solutions for the logistics execution industry across various regions, with a market cap of A$29.85 billion. Operations: The company focuses on delivering software solutions for the logistics execution industry, generating revenue of $698.66 million from its Internet Software & Services segment. WiseTech Global, a standout in Australia's tech landscape, has demonstrated robust financial health with its recent half-year earnings report showing a jump in net income to USD 106.4 million from USD 77.1 million the previous year. This performance is underpinned by a significant annual revenue growth rate of 20.5%, outstripping the broader Australian market's growth of 5.4%. The company's commitment to innovation is evident from its substantial R&D expenditure, aligning with industry trends towards enhanced software solutions and services. Additionally, WiseTech's strategic board reshuffles aim to bolster its governance and future growth strategy amidst high expectations for continued earnings expansion at an annual rate of 25.6%. Navigate through the intricacies of WiseTech Global with our comprehensive health report here. Gain insights into WiseTech Global's historical performance by reviewing our past performance report. Delve into our full catalog of 54 ASX High Growth Tech and AI Stocks here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:PYC ASX:QOR and ASX:WTC. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
